Protara Therapeutics, Inc. - Common Stock (TARA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
TARA on Nasdaq
Shares outstanding
38,466,645
Price per share
$5.33
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
26,208,473
Total reported value
$113,965,432
% of total 13F portfolios
0%
Share change
-3,400,477
Value change
-$10,353,742
Number of holders
79
Price from insider filings
$5.33
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Protara Therapeutics, Inc. - Common Stock (TARA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 11% +3.6% $18,406,290 +$559,893 4,231,331 +3.1% JANUS HENDERSON GROUP PLC 30 Sep 2025
BlackRock, Inc. 5.6% $6,388,762 2,143,880 BlackRock, Inc. 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% -50% $5,974,448 -$4,423,642 1,971,765 -43% RA Capital Management, L.P. 30 Jun 2025
Opaleye Management Inc. 4.7% -12% $7,473,600 -$410,400 1,730,000 -5.2% Opaleye Management, Inc. 31 Mar 2025
CITADEL ADVISORS LLC 4.7% $7,031,811 1,627,734 Kenneth Griffin 31 Dec 2024
Woodline Partners LP 3.9% $5,751,035 1,331,258 Woodline Partners LP 31 Dec 2024

As of 30 Sep 2025, 79 institutional investors reported holding 26,208,473 shares of Protara Therapeutics, Inc. - Common Stock (TARA). This represents 68% of the company’s total 38,466,645 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Protara Therapeutics, Inc. - Common Stock (TARA) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 11% 4,231,331 +3.1% 0.01% $18,363,977
BlackRock, Inc. 5.8% 2,229,368 +4% 0% $9,697,750
Velan Capital Investment Management LP 5.6% 2,139,000 0% 8.7% $9,304,650
Blackstone Inc. 5% 1,909,662 0% 0.04% $8,307,030
VANGUARD GROUP INC 5% 1,904,156 +5.7% 0% $8,283,078
ACORN CAPITAL ADVISORS, LLC 4.6% 1,752,115 0% 3.9% $7,621,700
Catalio Capital Management, LP 3.9% 1,500,793 -7.7% 1.2% $6,528,450
Integral Health Asset Management, LLC 3.6% 1,400,000 0% 0.44% $6,090,000
UBS Group AG 2.2% 843,074 -26% 0% $3,667,372
5AM Venture Management, LLC 2.1% 800,000 0% 1.3% $3,480,000
GEODE CAPITAL MANAGEMENT, LLC 2% 758,719 +1.9% 0% $3,301,348
MILLENNIUM MANAGEMENT LLC 1.8% 688,256 +22% 0% $2,993,914
BAKER BROS. ADVISORS LP 1.4% 536,832 0% 0.02% $2,335,219
CITADEL ADVISORS LLC 1.3% 502,454 +22% 0% $2,185,675
Driehaus Capital Management LLC 1.2% 444,444 0.01% $1,933,331
STEMPOINT CAPITAL LP 0.95% 363,666 -68% 0.32% $1,581,947
SUPERSTRING CAPITAL MANAGEMENT LP 0.94% 360,000 0% 1.5% $1,566,000
STATE STREET CORP 0.91% 350,091 +20% 0% $1,522,896
RENAISSANCE TECHNOLOGIES LLC 0.82% 314,300 +111% 0% $1,367,205
Assenagon Asset Management S.A. 0.8% 307,422 0% $1,337,286
MARSHALL WACE, LLP 0.74% 285,586 -21% 0% $1,242,299
Nuveen, LLC 0.74% 283,481 +179% 0% $1,233,142
CIBC WORLD MARKET INC. 0.71% 274,994 -5.7% 0% $1,196,224
NORTHERN TRUST CORP 0.61% 234,360 -5.6% 0% $1,019,466
OPPENHEIMER & CO INC 0.54% 206,973 -16% 0.01% $900,333

Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 308,334 $1,643,420 +$4,861 $5.33 1
2025 Q3 26,208,473 $113,965,432 -$10,353,742 $4.35 79
2025 Q2 29,714,732 $90,054,436 +$447,680 $3.03 76
2025 Q1 28,759,849 $123,767,729 -$8,349,026 $4.26 59
2024 Q4 29,670,168 $156,599,526 +$91,818,405 $5.28 60
2024 Q3 10,445,706 $19,115,471 +$384,364 $1.83 33
2024 Q2 10,449,817 $22,236,374 +$12,029,265 $2.08 38
2024 Q1 4,570,660 $18,342,843 +$911,041 $4.01 34
2023 Q4 4,357,920 $8,168,237 -$1,261,027 $1.88 30
2023 Q3 5,117,943 $8,547,441 -$31,849 $1.67 31
2023 Q2 5,136,537 $12,262,078 -$1,134,644 $2.39 28
2023 Q1 5,503,158 $16,886,987 +$77,617 $3.13 28
2022 Q4 5,478,113 $14,679,319 -$481,288 $2.68 29
2022 Q3 5,656,228 $16,718,296 -$789,370 $2.96 26
2022 Q2 5,927,042 $18,391,293 -$2,063,463 $2.93 31
2022 Q1 6,495,468 $33,192,511 -$1,990,162 $5.11 34
2021 Q4 6,872,165 $46,492,675 +$3,840,591 $6.75 36
2021 Q3 6,311,961 $43,679,692 -$8,598,514 $6.92 36
2021 Q2 7,110,843 $69,259,000 -$22,850,218 $9.74 38
2021 Q1 8,528,460 $134,015,000 -$11,645,346 $15.74 49
2020 Q4 8,775,745 $212,476,065 -$5,829,365 $24.21 48
2020 Q3 9,281,283 $156,208,097 +$91,825,921 $16.83 44
2020 Q2 3,696,566 $108,380,809 +$108,380,809 $29.32 31